Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Aaron Elliott Lisberg,Jacob Sands,Toshio Shimizu,Jonathan Greenberg,Penny Phillips,Ferdinand M. Guevara,Yutaka Noguchi,Tadashi Toki,Alexander Spira,Noboru Yamamoto,Melissa L. Johnson,Funda Meric-Bernstam,Kiyotaka Yoh,Edward B. Garon,Rebecca Suk Heist

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited 14|Views47

No score

Abstract

9619Background: TROP2 is an intracellular calcium signaling transducer overexpressed in NSCLC, portending poor survival. DS-1062 is a TROP2-targeting ADC with a novel topoisomerase 1 inhibitor (exa...

Translated text

Key words

antibody drug conjugate,lung cancer,cell-surface,non-small

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined